Dear Dr. Vechery:

Please refer to the following supplemental new drug applications (sNDAs), and their amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA):

NDA 209092/S-003 dated July 30, 2019, received July 30, 2019, for Kisqali® (ribociclib) tablets

NDA 209935/S-006 dated August 28, 2019, received August 28, 2019, for Kisqali® Femara® Co-pack (ribociclib tablets in combination with letrozole tablets)

Prior Approval supplement new drug application NDA 209092/S-003 provides for updates to Section 14 of the Prescribing Information to add efficacy data from study CLEE011E2301 (MONALEESA-7) to fulfill PMC 3453-1 from the July 18, 2018 approval letter for S-001.

In addition, this supplement proposes updates to Sections 8.7 (Renal Impairment) and 12.3 (Pharmacokinetics – Patients with Renal Impairment) of the Prescribing Information to reflect the results of the dedicated renal impairment study A2116 Part 2 in mild and moderate renal impairment. The proposed Prescribing Information maintains the current dosing recommendations for mild and moderate renal impairment.

Prior Approval supplemental new drug application NDA 209935/S-006, provides for the same updates as proposed in NDA 209092/S-003 for Kisqali®.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.\(^1\) Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.\(^2\)

The SPL will be accessible from publicly available labeling repositories.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for this application because necessary studies are impossible or highly impracticable in children. Breast cancer occurs, for the most part, in the adult population. The incidence of this cancer type in pediatric patients is extremely rare and as such, clinical pediatric studies are impossible or highly impracticable.

\(^1\) [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

\(^2\) We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).

U.S. Food and Drug Administration
Silver Spring, MD 20993
[www.fda.gov](http://www.fda.gov)
FULFILLMENT OF POSTMARKETING COMMITMENT

We refer to your supplemental new drug application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kisqali® (ribociclib) tablets.

We have received your submission dated July 30, 2019, containing the final report for the following postmarketing commitment listed in the July 18, 2018, approval letter for S-001.

3453-1 Submit the interim overall survival (OS) report with data and analysis; the final OS report with data and analysis from clinical trial MONALEESA-7 entitled: “A phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2 negative advanced breast cancer.

The timetable you submitted on July 13, 2018, states that you will conduct this study according to the following schedule:

Final Protocol Submission: 04/2017
Trial Completion: 12/2020
Interim OS Report Submission: 12/2019
Final OS Report Submission: 06/2021

We have reviewed your submission and conclude that the above commitment was fulfilled.

We remind you that there is a postmarketing commitment listed in the July 18, 2018, approval letter that is still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the Prescribing Information to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

Reference ID: 4548535
Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov. Information and Instructions for completing the form can be found at FDA.gov. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see FDA.gov.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Rajesh Venugopal, Senior Regulatory Project Manager, at (301) 796-4730.

Sincerely,

{See appended electronic signature page}

Laleh Amiri-Kordestani, MD
Supervisory Associate Director
Division of Oncology 1
Office of Oncologic Diseases
Center for Drug Evaluation and Research

**ENCLOSURE(S):**

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert

---

3 When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent version of a guidance, check the FDA guidance web page at [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).


6 [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm)

U.S. Food and Drug Administration
Silver Spring, MD 20993
[www.fda.gov](http://www.fda.gov)
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LALEH AMIRI KORDESTANI
01/21/2020 09:51:21 AM